This article has Open Peer Review reports available.
Effects of a nurse-coordinated prevention programme on health-related quality of life and depression in patients with an acute coronary syndrome: results from the RESPONSE randomised controlled trial
- Harald T. Jørstad†1,
- Madelon Minneboo†1Email author,
- Harold J. M. Helmes2,
- Nick D. Fagel1,
- Wilma J. Scholte op Reimer3,
- Jan G. P. Tijssen1 and
- Ron J. G. Peters1
© The Author(s). 2016
Received: 22 December 2015
Accepted: 10 June 2016
Published: 8 July 2016
Improvement of health-related quality of life (HRQOL) is an important goal in preventive cardiology. HRQOL is also related to depressive symptoms, which represent a common co-morbidity and risk factor in patients with an acute coronary syndrome (ACS). Comprehensive nurse-coordinated prevention programmes (NCPP) in secondary care have been shown to reduce cardiovascular risk, however their effects on HRQOL and depressive symptoms have not been evaluated. We therefore investigated HRQOL and depressive symptoms in a secondary analysis in the RESPONSE trial, evaluating the effect of a NCPP on cardiovascular risk.
RESPONSE was a multicentre (n = 11) randomised controlled trial in ACS-patients in secondary and tertiary healthcare settings evaluating a NCPP. The intervention consisted of four outpatient nurse clinic visits in the first 6 months after the index event, focusing on healthy lifestyles, biometric risk factors and medication adherence, in addition to usual care. The control group received usual care only. The outcome was change in HRQOL as measured by the MacNew questionnaire and change in depressive symptoms as measured by Beck’s Depression Inventory (BDI) questionnaire at 12-months follow-up relative to baseline.
Of 754 patients randomised, 615 were analysed for HRQOL; 120 for depressive symptoms. At baseline, HRQOL was 5.17 (SD 1.09) and 5.20 (SD1.04) (scale range 1.0 to 7.0) in the intervention and control group, respectively. At 12 months follow-up, HRQOL increased by 0.57 (SD 0.89) in the intervention group as compared with 0.42 (SD 0.90) in the control group (p = 0.03). This increase was observed across all relevant subscales. The BDI decreased by 1.9 in the intervention group as compared with 0.03 in the control group (p = 0.03) (scale range 1.0 to 63).
Participation in a NCPP is associated with a modest but statistically significant increase in HRQOL, and a decrease of depressive symptoms, both of which are highly relevant to patients. A reduction in depressive symptoms may in addition contribute to a reduction in the overall risk of recurrent events.
Dutch trials register: NTR1290. Registered 24 April 2008.
Patients with established coronary artery disease are at high risk of recurrent coronary events and mortality. Effective secondary prevention, including optimal medical therapy and lifestyle interventions (i.e. smoking cessation, healthy diet, weight loss/maintenance and regular exercise) can significantly reduce this risk [1, 2]. Nurses acting as disease managers have been demonstrated to be effective in reducing cardiovascular risk in several prevention programmes [3–6]. Therefore the European guideline on cardiovascular disease prevention and the World Health Organisation recommend nurse-coordinated prevention programmes (NCPP) to be integrated into healthcare systems [2, 7]. Such programmes are increasingly being implemented in clinical practice. We have previously shown that participation in a NCPP as part of the RESPONSE (Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialist) trial leads to a reduction in cardiovascular risk and a reduction of hospital admissions. This trial included patients with an acute coronary syndrome (ACS); most of who had multiple risk factors, including a high prevalence of lifestyle related risk factors. In short, the intervention group received nurse-coordinated care on top of usual care, while the control group received usual care only. We found that a NCPP improves risk factor control after 1 year. However, lifestyle-related risk factors, such as smoking and overweight, remained largely unchanged, with the exception of physical activity, where an improvement was observed (albeit self-reported) .
Health related quality of life (HRQOL), including emotional, physical and social well-being, is an important goal in preventive cardiology, in addition to optimal risk factor control . Patients with an unhealthy lifestyle have been shown to have a lower HRQOL . Nevertheless, lifestyle interventions have been shown to improve HRQOL . Furthermore, HRQOL is influenced by a wide range of factors, such as patient characteristics and emotions, but also by factors as the quality of information and communication, factors which are targeted by NCPPs.
Furthermore, HRQOL is related to depressive symptoms, and depression is a common comorbidity among ACS-patients, with an incidence in the year after an acute myocardial infarction ranging from 10 to 30 % per year [11–13]. Major and minor depressions have been shown to be independent risk factors for cardiovascular mortality [14, 15]. Recently the American Heart Association listed depression as a risk factor for adverse medical outcomes in ACS-patients . Depression is also associated with a higher prevalence of unhealthy behaviour, such as smoking and a sedentary lifestyle, and depression per se may also contribute to poorer cardiovascular outcomes [16–18].
Participation in a NCPP may improve HRQOL or depressive symptoms, resulting from continued care and attention to the patient’s personal situation. However, as NCPPs usually focus on risk factors, there may potentially be a detrimental effect on HRQOL or depressive symptoms if the attempted lifestyle changes are unsuccessful or if the effort to change one’s lifestyle is too arduous. For individual patients, smoking cessation, weight loss and diets, and limitations in alcohol intake may be perceived as a limitation of HRQOL, while the preventive effects (if successful) are not directly experienced (i.e. reduction of risk) [19, 20]. Therefore it is important to investigate whether a NCPP impacts on HRQOL and on depressive symptoms in a groups of ACS-patients and a high prevalence of CVD risk factors, including lifestyle related risk factors. We therefore aimed to investigate the change in HRQOL and depressive symptoms in the RESPONSE-population.
The RESPONSE trial was a multicentre, randomised controlled trial conducted in 11 hospitals in the Netherlands from June 2006 to July 2009. The study was designed to evaluate the impact of a practical, hospital-based NCPP on top of usual care in patients hospitalised for an ACS. The RESPONSE trial has been described in detail elsewhere [7, 21], and is briefly summarised below. (http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1290).
Eligible patients were 18–80 years of age, admitted for ACS (ST-segment myocardial infarction, non-ST-segment elevation myocardial infarction or unstable angina pectoris) The window of inclusion was up to 8 weeks after the date of discharge ACS. Exclusion criteria were: 1) unable to visit outpatient clinic 2) not available for follow-up 3) surgery or percutaneous coronary intervention expected within 8 weeks after inclusion 4) limited life expectancy (≤2 years) 5) previously enrolled in a NCPP, 6) congestive heart failure New York Heart Association class III or IV.
Patients were screened during or shortly after hospitalisation by their treating physician or a trained nurse. Patients were randomised using an online randomisation protocol. The online randomisation protocol consisted of a pre-generated block-stratified randomisation protocol (www.responsestudie.nl). Study personnel entered patients’ initials, date of birth and gender, and participating individuals were assigned a study identification number along with their allocation to either the intervention or control group. The randomisation protocol was designed and generated by an independent third party; study personnel had no influence on the randomisation process [7, 21]. The Academic Medical Center Ethical Review Board and institutional committees on human research of all recruiting hospitals approved the protocol and informed consent was obtained from all patients.
Patients randomised to the intervention group were invited to attend the NCPP in addition to usual care. This programme included 4 outpatient clinic visits to a cardiovascular nurse during the first 6 months after inclusion. Between 6 months and 1 year there were no visits to the NCPP.
The NCPP was developed based on national and international guidelines, focusing on (1) healthy lifestyles, (2) biometric risk factors, and (3) medication adherence [1, 2, 22]. Each visit was structured by pre-defined topics, including smoking status, dietary status, level of physical activity, and medication use. Smoking was defined as smoking prior to the index event, physically inactive was defined as less than 30 min of moderate physical activity per day for at least 5 days per week . The nurse provided advice on lifestyle and gave individual counselling and education as appropriate. During each visit weight, waist circumference, blood pressure, lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride), fasting glucose and HbA1c were measured. For each variable, a target value was defined. When this target value was not reached, medication could be changed (in collaboration with the treating physician), or the patient could be referred to another health professional, in addition to counselling and advice.
Study nurses were all registered nurses with a 4-year bachelor’s degree, and competent in cardiac care. As part of the study, nurses were trained during a 3 day course in the principles of motivational interviewing, a method often utilised to achieve lifestyle changes .
Patients randomised to the control group received usual care only, including visits to their treating cardiologists and other relevant specialists, and were offered cardiovascular rehabilitation according to national guidelines .
For our analysis, we used data collected at baseline and 12 months follow-up. Demographics (gender, educational status, work status, civil status and ethnicity), and cardiovascular risk factors (cardiovascular history, smoking status prior to index event, dietary status, level of physical activity and medication) were self-reported. Weight, height, waist circumferences, and blood pressure were objectively measured. Fasting blood samples were analysed for lipid profiles, glucose and HbA1c.
Health-related Quality of Life (HRQOL)
We used the MacNew Heart Disease Heart-related Quality of Life questionnaire (MacNew) to measure quality of life. MacNew is a self-administered instrument consisting 27 items related to three domains of HRQOL: emotional, physical and social quality of life. Each item is rated on a 7–point Likert scale, where ‘1’ indicates poor HRQOL and ‘7’ indicates good HRQOL. A total score is calculated by taking the average of the score on each item. Missing items do not contribute to the total score, and if more than 4 items were missing a total score is not calculated. An emotional subscale score is calculated by 14 items (questions 1, 2, 3, 4, 5, 6, 7, 8, 10, 15 and 18), a physical subscale score by 13 items (questions 2, 6, 9, 11, 14, 16, 17, 19, 20 and 21), and a social subscale score by 13 items (questions 11, 12, 13, 15, 22, 23 and 27). The MacNew has been shown to be a valid, reliable and responsive questionnaire for patients diagnosed with myocardial infarction and angina pectoris .
Data collection on depressive symptoms was added in a subset of patients (included in 6 hospitals) after initiation of the main study from September 2008 till July 2009 (protocol addendum). For depression screening, we used the Beck Depression Inventory (BDI). The BDI is a 21 item self-report questionnaire, developed to assess the presence and severity of depressive symptoms. Each item is rated on a 0–3 scale. A total score is presented as the sum of all items. The BDI is a reliable and validated measure of depressive symptomatology . A BDI score ≥ 10 indicates at least mild to moderate symptoms of depression and has been associated with poor prognosis in patients with myocardial infarction . For our analysis, patients with a BDI score higher or equal to 10 were classified as depressed, and patients with a BDI score lower than 10 were classified as non-depressed.
The impact of the NCPP on HRQOL was measured as the change in mean score of the MacNew questionnaire between baseline and 12 months, comparing the intervention group with the control group. The impact of the NCPP on depressive symptoms was similarly measured in a subgroup using the BDI. Both outcomes were secondary outcomes of the RESPONSE trial.
Continuous variables with a normal distribution were presented as mean and standard deviation (SD); categorical variables were presented as a number and percentage. Comparisons between groups for continuous data were analysed by independent samples t-tests or Mann Whitney U-tests, categorical data by χ2 tests or Fisher’s exact tests, as appropriate. The effect of time and group on the Macnew score was analysed by an analysis of variance (ANOVA) with repeated measures. SPSS statistics version 22.0 was used for all statistical analyses.
Included in HRQOL analysis
Included in depression analysis
n = 308
n = 307
n = 54
n = 66
Higher education (>8 years)
Employed (fulltime or part-time)
Previous vascular disease
Percutaneous coronary intervention
Coronary artery bypass surgery
Peripheral artery disease
No known previous cardiovascular disease
Cardiovascular risk factors
Positive family history
Diagnosed diabetes mellitus
Dyslipidaemia before hospital admission
Hypertension before hospital admission
Overweight (BMI > 25)
BDI ≥ 10
Change in MacNew score (HRQOL) from baseline to follow up
Change from baseline to 12 months
n = 308
n = 307
n = 308
n = 307
n = 308
n = 307
St. Error of the Mean
95 % C.I.
In patients with depression screening, the intervention group showed a decrease of 1.9 points as compared with 0.03 points in the control group (p = 0.03). The mean difference between the intervention and the control group was −1.84 points [(95 % C.I. -3.45 to −0.20) p = 0.03]. At 12 months, 12 patients in the intervention group were depressed as compared to 11 in the control group (p = ns).
The main finding of our study is that participation in a NCPP leads to an increase in HRQOL on top of improved risk factor control in patients who have been hospitalised for an ACS. This increase in HRQOL was seen across all the emotional, physical and socials subscales. Furthermore, a NCPP contributes to a reduction in depressive symptoms in ACS patients. However, there was no difference in the number of depressed patients between the intervention and control group based on a binary definition.
In addition to morbidity and mortality outcomes, HRQOL plays an important role in treatment strategies. A consensus statement from the Society for Cardiovascular Angiography and Interventions advocates that HRQOL outcomes should be measured in clinical trials and guidelines . In line with this, our study reports the HRQOL outcomes from a large, randomised controlled trial investigating the effect of such a programme on cardiovascular risk factors.
Several studies in patients with coronary artery disease have shown that HRQOL improves after treatment in patients with coronary artery disease undergoing a percutaneous coronary intervention, coronary artery bypass grafting or treated with optimal medical therapy [27–29]. In our study, revascularisation rates in both groups were comparable. Patients randomised to the intervention group received greater emphasis on improvement of risk profiles through adherence to medication and changing unhealthy lifestyles. Usual care, as provided in both groups, included visits to cardiologists, general practitioners and other health care personnel, and there were no restrictions in either group as to participation in cardiac rehabilitation programmes. Accordingly, the observed improvement in HRQOL was achieved against a background of a high level of usual care, and with excellent adherence to medication in both groups .
Clinically meaningful changes in the total score of the MacNew have been reported to be in the magnitude of 0.5, similar to our results . Although both groups showed improvement in quality of life, the intervention group improved more than the control group. Potential explanations for this improvement include more individual attention from the nurses, and their ability to respond to individual patient’s needs, as well as providing better information.
In the EuroAspire III survey (2006–2007), conducted in 8745 patients with coronary artery disease in 22 European countries, HRQOL was shown to be higher in patients adopting healthier lifestyles . However, the EuroAspire III survey was designed as a cross-sectional study, and the direction of the association between HRQOL and lifestyle is uncertain. Adding to their observations, our study shows prospectively that attending an NCPP (on top of usual care) improves both medication adherence and lifestyle components and leads to a greater improvement in HRQOL than usual care alone.
Murchie et al. (2004) investigated the effect of a NCPP on quality of life (QOL) as measured by Short-Form 36 (SF-36). At 12-months follow-up, they showed a significant improvement in 5 of 8 domains of SF-36, comparable with our findings . However, our NCPP took place in a hospital setting and, by comparison, we included younger patients (58 years vs 66 years) with a more recent coronary event. Furthermore, our measure of interest was HRQOL as opposed to generic QOL. In a cluster-randomised trial in primary practices, Khunti et al. (2007) found a slight increase in QOL (SF36) in patients with coronary heart disease attending specialist nurse managers as compared with usual care . This increase reached statistical significance in the domains of physical functioning, general health, vitality, social functioning and mental health. This study population consisted mainly of chronic patients, and the intervention was delivered in the primary practice.
Consistent with our findings, a meta-analysis by Ekers et al. showed that nurse-delivered collaborative care is an effective treatment for depression in patients with different chronic health problems, including in coronary heart disease. However, studies were included with nurse interventions specifically targeting depression, where nurses received brief periods of training for this purpose . In our study, nurses received training in motivational interviewing and secondary prevention, but not specifically for depression treatment, as depression treatment was not a pre-specified target in our study. Possibly, the nurse and the extra attention and care received by patients visiting a NCPP have, on their own, a modestly positive effect on depressive symptoms. Furthermore, while the mean decrease in BDI was greater in the intervention group as compared with the control group, this did not change the prevalence of the number of depressed patients at 12 months, with 12 (22 %) patients in the intervention group and 11 (17 %) patients in the control group having a BDI > 10 after 1 year.
Strengths and limitations
There are several strengths to our study. First, we assessed HRQOL in a large, contemporary randomised multicentre trial with a well-defined trial population. Second, the NCPP investigated in the trial was a practical intervention with clearly defined intervention components, facilitating future implementation of comparable programmes. Finally, complete questionnaires on HRQOL were available in the majority of patients, making selection bias unlikely.
Some limitations should be considered when interpreting our results. First, we did not collect data on systolic left ventricular (dys) function. However, no patients in our trial had severe, symptomatic heart failure, as we excluded all patients with heart failure NYHA class III or IV. Only 6 patients (in the control group) were hospitalised for congestive heart failure during follow-up, making congestive heart failure unlikely as a cause for the slight difference in HRQOL observed between the groups . Second, we excluded patients >80 years of age. While secondary prevention should always be considered in the context of life expectancy, improvements in HRQOL would likely be of value in elderly and frail patients. While it is conceivable that an increase in HRQOL may be observed in patients older than included in our trial, we cannot infer this from our data. Additional factors, such comorbidity and frailty should be taken into account when evaluating comparable interventions in these populations [35, 36]. Third, our trial included a slightly lower proportion of women as compared with other national and international surveys. In the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) III survey, performed in 22 countries in Europe (including the Netherlands), 27 % of participants were women . Fourth, we collected data about depression in a small sample, as this component of the study was added to the protocol after initiation of the main trial. Although only a modest number of patients were screened for depressive symptoms, we observed a small but significant difference between the groups.
Our study suggests that participation in a nurse-coordinated prevention programme with four outpatient clinic visits in addition to usual care leads to a small but significant improvement in HRQOL in patients with an ACS. This improvement was seen across the emotional, physical and social dimensions of HRQOL. In addition to the effect on HRQOL, the NCPP was found to reduce depressive symptoms in these patients. In conclusion, our study shows that a NCPP has a favourable effect on HRQOL and depressive symptoms in patients who have been hospitalised for an ACS.
ACS, acute coronary syndrome; BDI, Beck’s Depression Inventory; HRQOL, Health-related quality of life; NCPP, nurse-coordinated prevention programmes; QoL, quality of life; RESPONSE, Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialist; SD, standard deviation; SF-36, Short-Form 36.
We would like to acknowledge the contribution of all the RESPONSE trial nurses and patients who participated in the trial.
The study was sponsored by an unrestricted grant from AstraZeneca, the Netherlands. The sponsor had no role in the design, data collection, data analysis, data interpretation and writing.
Availability of data and materials
Request for analyses of de-identified data from this trial should be directed to: HTJ (firstname.lastname@example.org).
HTJ, JGPT and RJG participated in the design of the study. HTJ, HJMH and NDF were responsible for the coordination and acquisition of the data. HTJ and MM performed the statistical analysis. HTJ, MM, WJMSR, and RJG contributed to the preparation and critical review of the manuscript. RJG obtained funding for the study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The RESPONSE trial was approved by the Academic Medical Center Ethical Review Board and institutional committees on human research of all recruiting hospitals and informed consent was obtained from all patients.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Smith Jr SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458–73.View ArticlePubMedGoogle Scholar
- Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701.View ArticlePubMedGoogle Scholar
- Berra K, Miller NH, Fair JM. Cardiovascular disease prevention and disease management: A critical role for nursing. J Cardiopulm Rehabil. 2006;26:197–206.View ArticlePubMedGoogle Scholar
- Mainie PM, Moore G, Riddell JW, Adgey AA. To examine the effectiveness of a hospital-based nurse-led secondary prevention clinic. Eur J Cardiovasc Nurs. 2005;4:308–13.View ArticlePubMedGoogle Scholar
- Campbell NC, Ritchie LD, Thain J, Deans HG, Rawles JM, Squair JL. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart. 1998;80:447–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008;371:1999–2012.View ArticlePubMedGoogle Scholar
- Jorstad HT, von Birgelen C, Alings AM, et al. Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart. 2013;99:1421–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Shephard RJ, Franklin B. Changes in the quality of life: a major goal of cardiac ehabilitation. J Cardiopulm Rehabil. 2001;21:189–200.View ArticlePubMedGoogle Scholar
- Savolainen J, Kautiainen H, Miettola J, Niskanen L, Mantyselka P. Low quality of life and depressive symptoms are connected with an unhealthy lifestyle. Scand J Public Health. 2014;42:163–70.View ArticlePubMedGoogle Scholar
- Govil SR, Weidner G, Merritt-Worden T, Ornish D. Socioeconomic status and improvements in lifestyle, coronary risk factors, and quality of life: the Multisite Cardiac Lifestyle Intervention Program. Am J Public Health. 2009;99:1263–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Honig A, Lousberg R, Wojciechowski FL, Cheriex EC, Wellens HJ, van Praag HM. Depression following a first heart infarct; similarities with and differences from ‘ordinary’ depression. Ned Tijdschr Geneeskd. 1997;141:196–9.PubMedGoogle Scholar
- Strik JJ, Lousberg R, Cheriex EC, Honig A. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. J Psychosom Res. 2004;56:59–66.View ArticlePubMedGoogle Scholar
- van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66:814–22.View ArticlePubMedGoogle Scholar
- Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999–1005.View ArticlePubMedGoogle Scholar
- Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations: A Scientific Statement From the American Heart Association. Circulation. 2014.Google Scholar
- Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet. 2001;357:1929–32.View ArticlePubMedGoogle Scholar
- Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. Jama. 2008;300:2379–88.View ArticlePubMedPubMed CentralGoogle Scholar
- Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med. 2000;160:1818–23.View ArticlePubMedGoogle Scholar
- Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification--a 2-y follow-up study. Int J Obes Relat Metab Disord. 2003;27:1233–41.View ArticlePubMedGoogle Scholar
- McClave AK, Dube SR, Strine TW, Mokdad AH. Associations between health-related quality of life and smoking status among a large sample of U.S. adults. Prev Med. 2009;48:173–9.View ArticlePubMedGoogle Scholar
- Jorstad HT, Alings AM, Liem AH, et al. RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists: Study design, objectives and expected results. Neth Heart J. 2009;17:322–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Smulders YM, Burgers JS, Scheltens T, van Hout BA, Wiersma T, Simoons ML. Clinical practice guideline for cardiovascular risk management in the Netherlands. Neth J Med. 2008;66:169–74.PubMedGoogle Scholar
- Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55:305–12.PubMedPubMed CentralGoogle Scholar
- De Gucht V, Van Elderen T, van der Kamp L, Oldridge N. Quality of life after myocardial infarction: translation and validation of the MacNew Questionnaire for a Dutch population. Qual Life Res. 2004;13:1483–8.View ArticlePubMedGoogle Scholar
- Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes care. 2014; 37: 1544–53.Google Scholar
- Blankenship JC, Marshall JJ, Pinto DS, et al. Effect of percutaneous coronary intervention on quality of life: a consensus statement from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;81:243–59.View ArticlePubMedGoogle Scholar
- Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med. 2011;364:1016–26.View ArticlePubMedGoogle Scholar
- Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677–87.View ArticlePubMedGoogle Scholar
- Rumsfeld JS, Magid DJ, Plomondon ME, et al. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. J Am Coll Cardiol. 2003;41:1732–8.View ArticlePubMedGoogle Scholar
- Dixon T, Lim LL, Oldridge NB. The MacNew heart disease health-related quality of life instrument: reference data for users. Qual Life Res. 2002;11:173–83.View ArticlePubMedGoogle Scholar
- De Smedt D, Clays E, Annemans L, et al. The association between self-reported lifestyle changes and health-related quality of life in coronary patients: the EUROASPIRE III survey. Eur J Prev Cardiol. 2014;21:796–805.View ArticlePubMedGoogle Scholar
- Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ. 2003;326:84.View ArticlePubMedPubMed CentralGoogle Scholar
- Khunti K, Stone M, Paul S, et al. Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart. 2007;93:1398–405.View ArticlePubMedPubMed CentralGoogle Scholar
- Ekers D, Murphy R, Archer J, Ebenezer C, Kemp D, Gilbody S. Nurse-delivered collaborative care for depression and long-term physical conditions: a systematic review and meta-analysis. J Affect Disord. 2013;149:14–22.View ArticlePubMedGoogle Scholar
- Moretti C, Quadri G, D’Ascenzo F, et al. THE STORM (acute coronary Syndrome in paTients end Of life and Risk assesMent) study. Emerg Med J. 2016;33:10–6.View ArticlePubMedGoogle Scholar
- Kang L, Zhang SY, Zhu WL, et al. Is frailty associated with short-term outcomes for elderly patients with acute coronary syndrome? J Geriatr Cardiol. 2015;12:662–7.PubMedPubMed CentralGoogle Scholar
- Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121–37.View ArticlePubMedGoogle Scholar